Diabetic macular oedema is the most common cause of diabetic retinopathy-induced vision loss. Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian-specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti-vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head-to-head comparisons between the different anti-vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti-vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.

1. Aiello, L. P., Avery, R. L., Arrigg, P. G., et al. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine, 331, 1480–1487.
2. Avery, R. L., & Gordon, G. M. (2016). Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis. JAMA Ophthalmology, 134, 21–29.
3. Bates, D. O. (2010). Vascular endothelial growth factors and vascular permeability. Cardiovascular Research, 87, 262–271.
4. Boyer, D. S., Nguyen, Q. D., Brown, D. M., Basu, K., & Ehrlich, J. S. (2015). Outcomes with as-needed ranibizumab after initial monthly therapy: Long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology, 122, 2504–2513.
5. Boyer, D. S., Yoon, Y. H., Belfort, R., Jr., et al. (2014). Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology, 121, 1904–1914.
6. Bressler, S. B., Ayala, A. R., Bressler, N. M., et al. (2016). Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmology, 134, 278–285.
7. Brown, D. M., Nguyen, Q. D., Marcus, D. M., et al. (2013). Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology, 120, 2013–2022.
8. Brown, D. M., Schmidt-Erfurth, U., Do, D. V., et al. (2015). Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology, 122, 2044–2052.
9. Campochiaro, P. A., Brown, D. M., Pearson, A., et al. (2012). Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology, 119, 2125–2132.
10. Campochiaro, P. A., Hafiz, G., Shah, S. M., et al. (2010). Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology, 117, 1393–1399.
11. Chan, J. C., Malik, V., Jia, W., et al. (2009). Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA, 301, 2129–2140.
12. Chen, Y. Y., Chang, P. Y., & Wang, J. K. (2017). Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: Analysis of response to aflibercept. Asia-Pacific Journal of Ophthalmology, 6, 250–255.
13. Cheung, C. M., & Wong, T. Y. (2014). Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. Journal of Internal Medicine, 276, 140–153.
14. Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. The Lancet, 376, 124–136.
15. Cheung, N., Wong, I. Y., & Wong, T. Y. (2014). Ocular anti-VEGF therapy for diabetic retinopathy: Overview of clinical efficacy and evolving applications. Diabetes Care, 37, 900–905.
16. Ciulla, T. A., Amador, A. G., & Zinman, B. (2003). Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies. Diabetes Care, 26, 2653–2664.
17. Ciulla, T. A., Hussain, R. M., Ciulla, L. M., Sink, B., & Harris, A. (2016). Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina, 36, 1292–1297.
18. Cunha-Vaz, J., Ashton, P., Iezzi, R., et al. (2014). Sustained delivery fluocinolone acetonide vitreous implants: Long-term benefit in patients with chronic diabetic macular edema. Ophthalmology, 121, 1892–1903.
19. Diabetic Retinopathy Clinical Research Network, Elman, M. J., Qin, H., et al. (2012). Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three-year randomized trial results. Ophthalmology, 119, 2312–2318.
20. Do, D. V., Nguyen, Q. D., Boyer, D., et al. (2012). One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology, 119, 1658–1665.
21. Elman, M. J., Aiello, L. P., Beck, R. W., et al. (2010). Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 117, 1064–1077.
22. Elman, M. J., Ayala, A., Bressler, N. M., et al. (2015). Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology, 122, 375–381.
23. Fenwick, E. K., Xie, J., Ratcliffe, J., et al. (2012). The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Investigative Ophthalmology & Visual Science, 53, 677–684.
24. Fong, D. S., Aiello, L., Gardner, T. W., et al. (2004). Retinopathy in diabetes. Diabetes Care, 27, S84–S87.
25. Fraser-Bell, S., Lim, L. L., Campain, A., et al. (2016). Bevacizumab or dexamethasone implants for DME: 2-year results from the BEVORDEX Study. Ophthalmology, 123, 1399–1401.
26. Gillies, M. C., Lim, L. L., Campain, A., et al. (2014). A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology, 121, 2473–2481.
27. Gonzalez, V. H., Campbell, J., Holekamp, N. M., et al. (2016). Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: Analysis of Protocol I data. American Journal of Ophthalmology, 172, 72–79.
28. Gross, J. G., Glassman, A. R., Jampol, L. M., et al. (2015). Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA, 314, 2137–2146.
29. Heier, J. S., Korobelnik, J. F., Brown, D. M., et al. (2016). Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology, 123, 2376–2385.
30. Heng, L. Z., Sivaprasad, S., Crosby-Nwaobi, R., et al. (2016). A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema: OZLASE study. British Journal of Ophthalmology, 100, 802–807.
31. International Council of Ophthalmology. (2016). Updated 2017 ICO guidelines for diabetic eye care. International Council of Ophthalmology.
32. Ishibashi, T., Li, X., Koh, A., et al. (2015). The REVEAL study: Ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology, 122, 1402–1415.
33. Jampol, L. M., Glassman, A. R., Bressler, N. M., Wells, J. A., & Ayala, A. R. (2016). Anti-vascular endothelial growth factor comparative effectiveness trial for diabetic macular edema: Additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmology, 134, 134.
34. Kanda, A., Noda, K., Saito, W., & Ishida, S. (2015). Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy. Scientific Reports, 5, 17946.
35. Korobelnik, J. F., Do, D. V., Schmidt-Erfurth, U., et al. (2014). Intravitreal aflibercept for diabetic macular edema. Ophthalmology, 121, 2247–2254.
36. Lang, G. E. (2012). Diabetic macular edema. Ophthalmologica, 227, 21–29.
37. Lee, R., Wong, T. Y., & Sabanayagam, C. (2015). Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision, 2, 17.
38. Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012). Age-related macular degeneration. The Lancet, 379, 1728–1738.
39. Lim, L. S., Ng, W. Y., Mathur, R., et al. (2015). Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clinical Ophthalmology, 9, 1715–1718.
40. Mathew, C., Yunirakasiwi, A., & Sanjay, S. (2015). Updates in the management of diabetic macular edema. Journal of Diabetes Research, 2015, 794036.
41. Michaelides, M., Kaines, A., Hamilton, R. D., et al. (2010). A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema: BOLT study 12-month data: Report 2. Ophthalmology, 117, 1078–1086.
42. Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al. (2011). The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 118, 615–625.
43. Mitchell, P., Massin, P., Bressler, S., et al. (2015). Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: The RESTORE extension study. Current Medical Research and Opinion, 31, 1967–1975.
44. Mitchell, P., & Wong, T. Y. (2014). Management paradigms for diabetic macular edema. American Journal of Ophthalmology, 157, 505–513.
45. Mohamed, Q., Gillies, M. C., & Wong, T. Y. (2007). Management of diabetic retinopathy: A systematic review. JAMA, 298, 902–916.
46. Negi, A., & Marmor, M. F. (1984). Healing of photocoagulation lesions affects the rate of subretinal fluid resorption. Ophthalmology, 91, 1678–1683.
47. Nguyen, Q. D., Brown, D. M., Marcus, D. M., et al. (2012). Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology, 119, 789–801.
48. Park, Y. G., Kim, E. Y., & Roh, Y. J. (2014). Laser-based strategies to treat diabetic macular edema: History and new promising therapies. Journal of Ophthalmology, 2014, 769213.
49. Polizzi, S., & Mahajan, V. B. (2015). Intravitreal anti-VEGF injections in pregnancy: Case series and review of literature. Journal of Ocular Pharmacology and Therapeutics, 31, 605–610.
50. Rajendram, R., Fraser-Bell, S., Kaines, A., et al. (2012). A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy: BOLT in the management of diabetic macular edema: 24-month data: Report 3. Archives of Ophthalmology, 130, 972–979.
51. Ramasamy, K., Raman, R., & Tandon, M. (2013). Current state of care for diabetic retinopathy in India. Current Diabetes Reports, 13, 460–468.
52. Ramu, J., Yang, Y., Menon, G., et al. (2015). A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema: OZDRY study. Eye, 29, 1603–1612.
53. Romero-Aroca, P. (2011). Managing diabetic macular edema: The leading cause of diabetes blindness. World Journal of Diabetes, 2, 98–104.
54. Sato, S., Shinoda, H., Nagai, N., et al. (2017). Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice. Medicine, 96, e6459.
55. Schmidt-Erfurth, U., Lang, G. E., Holz, F. G., et al. (2014). Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE extension study. Ophthalmology, 121, 1045–1053.
56. Shahidi, M., Ogura, Y., Blair, N. P., & Zeimer, R. (1994). Retinal thickness change after focal laser treatment of diabetic macular oedema. British Journal of Ophthalmology, 78, 827–830.
57. Sivaprasad, S., Gupta, B., Crosby-Nwaobi, R., & Evans, J. (2012). Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective. Survey of Ophthalmology, 57, 347–370.
58. Sohn, H. J., Han, D. H., Kim, I. T., et al. (2011). Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. American Journal of Ophthalmology, 152, 686–694.
59. Stefanini, F. R., Badaro, E., Falabella, P., et al. (2014). Anti-VEGF for the management of diabetic macular edema. Journal of Immunology Research, 2014, 632307.
60. Tan, G. S., Cheung, N., Simó, R., Cheung, G. C., & Wong, T. Y. (2017). Diabetic macular oedema. The Lancet Diabetes & Endocrinology, 5, 143–155.
61. Ting, D. S., Cheung, G. C., & Wong, T. Y. (2016). Diabetic retinopathy: Global prevalence, major risk factors, screening practices and public health challenges: A review. Clinical & Experimental Ophthalmology, 44, 260–277.
62. Wells, J. A., III, Glassman, A. R., & Jampol, L. M. (2015). Targeting the effect of VEGF in diabetic macular edema. The New England Journal of Medicine, 373, 481–482.
63. Wells, J. A., Glassman, A. R., Ayala, A. R., et al. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England Journal of Medicine, 372, 1193–1203.
64. Wells, J. A., Glassman, A. R., Ayala, A. R., et al. (2016). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology, 123, 1351–1359.
65. World Health Organization. (2016). Diabetes factsheet number 312. http://www.who.int/mediacentre/factsheets/fs312/en/
66. Wright, S., Yelland, M., Heathcote, K., Ng, S. K., & Wright, G. (2009). Fear of needles: Nature and prevalence in general practice. Australian Family Physician, 38, 172–176.
67. Yang, W., Lu, J., Weng, J., et al. (2010). Prevalence of diabetes among men and women in China. The New England Journal of Medicine, 362, 1090–1101.
68. Yau, J. W., Rogers, S. L., Kawasaki, R., et al. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35, 556–564.
69. Yoon, K. H., Lee, J. H., Kim, J. W., et al. (2006). Epidemic obesity and type 2 diabetes in Asia. The Lancet, 368, 1681–1688.
70. Zheng, Y., Lamoureux, E. L., Lavanya, R., et al. (2012). Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: The Singapore Indian Eye Study. Ophthalmology, 119, 2119–2124.